Mereo BioPharma Group plc
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation United Kingdom
Country United Kingdom
Business Address ONE CAVENDISH PLACE, LONDON, , W1G 0QF
Mailing Address ONE CAVENDISH PLACE, LONDON, , W1G 0QF
Phone 4403330237300
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024 FY
$10.00M
Revenue
-$43.25M
Net Income
$60.97M
Stockholders' Equity
$69.80M
Cash & Equivalents
$-0.04
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 6, 2026 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
Material Events
8-K Other January 12, 2026
High Impact
- Mereo BioPharma has a cash runway extending until mid-2027, providing a solid timeframe for operations.
- The company had approximately $41 million in cash and cash equivalents as of December 31, 2025.
8-K Other December 29, 2025
High Impact
- Mereo BioPharma announced results from two Phase 3 clinical trials (Orbit and Cosmic) for setrusumab (UX143) in osteogenesis imperfecta (OI).
- Setrusumab significantly improved bone mineral density (BMD) in patients.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.